desipramine has been researched along with levodopa in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (34.15) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 9 (21.95) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 2 (4.88) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ogren, SO; Ross, SB | 1 |
| Lippmann, W; Pugsley, TA | 1 |
| Lippman, W; Pugsley, TA | 1 |
| Eplov, L; Nielsen, M; Scheel-Krüger, J | 1 |
| Monti, JM; Ruiz, M | 1 |
| Männistö, PT; Törnwall, M | 1 |
| Berman, ML; Tennant, F | 1 |
| el-Awar, M; Freedman, M; Goldenberg, L; Little, J; Seeman, P; Solomon, P | 1 |
| Jackson, DM; Jenkins, OF | 1 |
| Liskowsky, DR; Potter, LT | 1 |
| Blask, DE; Stockmeier, CA | 1 |
| Markham, CH | 1 |
| Kadzielawa, K | 1 |
| Hallman, H; Jonsson, G | 1 |
| Stricker, EM; Zigmond, MJ | 1 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Asanuma, M; Kawai, M; Kohno, M; Masumizu, T; Mori, A; Ogawa, N; Tanaka, K | 1 |
| Goshima, Y; Misu, Y; Miyamae, T; Nakamura, S; Ueda, H; Yue, JL | 1 |
| Allikmets, L; Matto, V; Skrebuhhova, T | 1 |
| Fotteler, B; Jorga, KM; Modi, M; Rabbia, M | 1 |
| Buitelaar, JK; Kemner, C; Kenemans, JL; Koelega, HS; Maes, RA; Overtoom, CC; van der Gugten, J; van der Molen, MW; van Engeland, H; Verbaten, MN; Westenberg, H | 1 |
| Bartalucci, A; Biagioni, F; Ferrucci, M; Fornai, F; Fulceri, F; Galli, V; Lazzeri, G; Paparelli, A; Ruggieri, S | 1 |
| Guo, A; Lu, H; Yin, Y; Zhang, S | 1 |
| Arai, A; Kannari, K; Kawarabayashi, T; Kimura, T; Shen, H; Shoji, M; Suzuki, C; Tomiyama, M; Watanabe, M | 1 |
| Barone, P | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Chotibut, T; Fields, V; Salvatore, MF | 1 |
| Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
1 review(s) available for desipramine and levodopa
| Article | Year |
|---|---|
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dopamine Agonists; Humans; Levodopa; Nortriptyline; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2011 |
2 trial(s) available for desipramine and levodopa
| Article | Year |
|---|---|
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
Topics: Adult; Antiparkinson Agents; Benzophenones; Cross-Over Studies; Desipramine; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Hemodynamics; Humans; Levodopa; Male; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Choice Behavior; Desipramine; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxyindoleacetic Acid; Inhibition, Psychological; Levodopa; Male; Methylphenidate; Prolactin; Reaction Time | 2003 |
38 other study(ies) available for desipramine and levodopa
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Behavior, Animal; Brain; Clomipramine; Desipramine; Dopamine; Drug Synergism; Levodopa; Male; Mice; Motor Activity; Neurons; Norepinephrine; Reserpine; Serotonin | 1977 |
Effect of acute and chronic treatment of tandamine, a new heterocyclic antidepressant, on biogenic amine metabolism and related activities.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Amines; Catecholamines; Desipramine; Heterocyclic Compounds; Indoles; Levodopa; Male; Mice; Norepinephrine; Phenethylamines; Rats; Receptors, Muscarinic; Time Factors | 1979 |
Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities.
Topics: Amitriptyline; Animals; Apomorphine; Biogenic Amines; Brain; Desipramine; Drug Synergism; Gastric Juice; Imipramine; In Vitro Techniques; Levodopa; Mice; Morpholines; Myocardium; Norepinephrine; Oxotremorine; Pupil; Rats; Reflex; Reserpine; Serotonin; Tyramine; Viloxazine | 1976 |
The effect of amitriptyline, desipramine and imipramine on the vivo brain synthesis of 3H-noradrenaline from 3H-L-dopa in the rat.
Topics: 3-Methoxy-4-hydroxyphenylethanol; 3,4-Dihydroxyphenylacetic Acid; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Benserazide; Brain; Chromatography, Thin Layer; Desipramine; Dopamine; Imipramine; Levodopa; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Normetanephrine; Rats; Tryptamines | 1975 |
Reversal of the 6-hydroxydopamine-induced suppression of a CAR by drugs facilitating central catecholaminergic mechanisms.
Topics: Amphetamine; Animals; Avoidance Learning; Behavior, Animal; Catecholamines; Clonidine; Desipramine; Hydroxydopamines; Injections, Intraventricular; Levodopa; Male; Norepinephrine; Phenelzine; Rats | 1975 |
Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Topics: Amphetamine; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clorgyline; Convulsants; Desipramine; Drug Interactions; Lethal Dose 50; Levodopa; Male; Mice; Motor Activity; Nitriles; Nomifensine; Pentanones; Selegiline; Synaptic Transmission; Yohimbine | 1991 |
Stepwise detoxification from cocaine. A promising regimen.
Topics: Adolescent; Adult; Amantadine; Bromocriptine; Cocaine; Desipramine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Substance Withdrawal Syndrome; Substance-Related Disorders; Tryptophan; Tyrosine | 1988 |
Response of tardive and L-dopa-induced dyskinesias to antidepressants.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Trazodone | 1987 |
Bromocriptine potentiates the behavioural effects of directly and indirectly acting dopamine receptor agonists in mice.
Topics: alpha-Methyltyrosine; Animals; Bromocriptine; Desipramine; Drug Synergism; Fluoxetine; Haloperidol; Levodopa; Male; Methyltyrosines; Mice; Motor Activity; Nomifensine; Receptors, Dopamine; Reserpine | 1985 |
A pre-positron emission tomography study of L-3,4-dihydroxy-[3H]phenylalanine distribution in the rat.
Topics: Animals; Apomorphine; Autoradiography; Brain; Corpus Striatum; Desipramine; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra; Tissue Distribution; Tomography, Emission-Computed | 1985 |
Neuropharmacological modification of central catecholamines: effects on pinealectomy-induced convulsions.
Topics: alpha-Methyltyrosine; Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Catecholamines; Clonidine; Desipramine; Levodopa; Male; Methyltyrosines; Parathyroid Glands; Pineal Gland; Rats; Reserpine; Seizures; Timolol | 1986 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chlordiazepoxide; Chorea; Desipramine; Diazepam; Dietary Proteins; Enzyme Inhibitors; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Physical Exertion; Picolinic Acids; Prochlorperazine; Sex Factors; Stress, Psychological | 1974 |
Dopamine receptor in the reward system of the rat.
Topics: Amantadine; Animals; Apomorphine; Benzyl Compounds; Cortical Synchronization; Desipramine; Dihydroxyphenylalanine; Dopamine; Electrodes, Implanted; Electroencephalography; Haloperidol; Hydrazines; Hypothalamus; Levodopa; Male; Rats; Receptors, Drug; Reward; Self Stimulation; Time Factors | 1974 |
Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP4 on central noradrenaline neurons.
Topics: Amines; Animals; Benzylamines; Catecholamines; Central Nervous System; Desipramine; Female; In Vitro Techniques; Levodopa; Male; Neurons; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Synaptosomes | 1984 |
Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Desipramine; Dopamine; Feeding Behavior; Hydroxydopamines; Kinetics; Levodopa; Male; Pargyline; Rats | 1980 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.
Topics: Animals; Bromocriptine; Carbidopa; Corpus Striatum; Desipramine; Dopamine; Free Radical Scavengers; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine | 1994 |
Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Desipramine; Dopamine Agents; Ergolines; Hydrazines; Injections, Intraventricular; Levodopa; Male; Microdialysis; Motor Activity; Nerve Fibers; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereoisomerism | 1994 |
The effect of antidepressants on rat aggressive behavior in the electric footshock and apomorphine-induced aggressiveness paradigms.
Topics: Aggression; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Apomorphine; Citalopram; Desipramine; Dopamine Agents; Electroshock; Fluoxetine; Levodopa; Male; Pain Measurement; Rats; Rats, Wistar; Tryptophan | 1998 |
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Locus Coeruleus; Male; Neurons; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Rotarod Performance Test; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2007 |
Increased dopaminergic signaling impairs aversive olfactory memory retention in Drosophila.
Topics: Animals; Desipramine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drosophila melanogaster; Drosophila Proteins; Levodopa; Memory; Neurons; Signal Transduction; Smell | 2008 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models, Animal; Dopamine; Extracellular Matrix; Levodopa; Male; Microdialysis; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Synapses; Synaptic Transmission | 2008 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals.
Topics: Animals; Corpus Striatum; Denervation; Desipramine; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Phosphorylation; Rats; Rats, Sprague-Dawley; Substantia Nigra; Synapses | 2014 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus | 2016 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipruritics; Corpus Striatum; Desipramine; Dopamine; Levodopa; Norepinephrine; Oxidopamine; Parkinson Disease; Platelet Aggregation Inhibitors; Rats; Serotonin | 2022 |